Lump sum or DCA, the latest on Ozempic & a baby Berkshire?

Haven't heard much about Ozempic lately? Let us change that and bring you up to speed on some wild developments in the world of weight loss drugs.In this episode we cover:How Novo Nordisk's latest drug has been twice as effective as their existing drugs in early trialsThe growing list of competitors to OzempicWhy these drugs could be incredible technology but less-than-incredible investments from hereA new company trying to copy Berkshire Hathaway's playbookThe impressive first 20 years of this company's Berkshire-lite playbookWe answer the age-old question: should I invest in a lump sum or dollar cost average?Resources discussed: Markel Group's 2023 shareholder letterDCA v Lump Sum: Nick Magulli studyDCA v Lump Sum: Morgan Stanley studyDCA v Lump Sum: Vanguard studyDCA v Lump Sum: Morningstar studyJoin the Facebook Discussion GroupPick up our book Don’t Stress Just InvestHave a question? Ask via our website and we'll answer it on the podcast.—------In the spirit of reconciliation, Equity Mates Media and the hosts of Equity Mates Investing acknowledge the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respects to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander people today. —------Equity Mates Investing is a product of Equity Mates Media. This podcast is intended for education and entertainment purposes. Any advice is general advice only, and has not taken into account your personal financial circumstances, needs or objectives. Before acting on general advice, you should consider if it is relevant to your needs and read the relevant Product Disclosure Statement. And if you are unsure, please speak to a financial professional. Equity Mates Media operates under Australian Financial Services Licence 540697. Hosted on Acast. See acast.com/privacy for more information.